Roquette acts to protect mannitol patent

Published: 25-May-2007
Ingredients Regulatory Patient Experience

Roquette FrEres has filed suit for patent infringement against SPI Pharma, Inc and Drytec Ltd, in the US District Court for the District of Delaware.


Roquette FrEres has filed suit for patent infringement against SPI Pharma, Inc and Drytec Ltd, in the US District Court for the District of Delaware.

The complaint alleges that the defendants' spray-dried mannitol products including MANNOGEM EZ Spray Dried Mannitol infringe Roquette's patented technology.

Roquette's US Patent Nr. 5,573,777, filed in 1993, protects a new physical form of mannitol that maximises performance as a directly compressible excipient in the pharmaceutical industry.

Mannitol (PEARLITOL) offers excellent tableting characteristics as well as the advantage of being non-cariogenic and non-hygroscopic, says Roquette. Its controlled particle size distribution also allows good flow and dissolution properties while minimising dust and preventing explosions during production or packaging.

  • Companies:
  • Roquette Freres
See more

You may also like

Ingredients

Experience is everything: excipients and their role in enhancing patient-centricity

Read more
It’s a hard pill to swallow, but medication adherence is one of the toughest challenges facing the pharmaceutical industry today, writes Arnaud Verhaeghe, Marketing Director, Pharma Oral Dosage at Roquette

Trending Articles

  1. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  2. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  3. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  4. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
  5. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Ingredients

Experience is everything: excipients and their role in enhancing patient-centricity

It’s a hard pill to swallow, but medication adherence is one of the toughest challenges facing the pharmaceutical industry today, writes Arnaud Verhaeghe, Marketing Director, Pharma Oral Dosage at Roquette
Ingredients

Roquette boosts customer support with new digital pharma marketplace

The e-commerce platform will provide users with access to Roquette’s trusted and reliable flagship pharmaceutical and biopharmaceutical offering at smaller quantities for the first time
Distribution

Roquette names Barentz a strategic partner for US distribution

Distributor will carry the entire Roquette pharmaceutical portfolio for customers in the United States
Ingredients

Roquette acquires a majority stake in Crest Cellulose

Crest Cellulose, based in India, is a leading manufacturer of pharmaceutical excipients
Media

Roquette and SKEMA business school sign partnership agreement

Driven by a mutual desire for innovation and international expansion, the two partners will jointly develop a series of actions in the next 3 years
Ingredients

Roquette signs agreement to acquire Itacel

Itacel, a leading player in Brazil and Latin America, is Blanver’s shareholders excipients division
Ingredients

Roquette commits to biopharma market

Reinforces position as a supplier of excipients and raw materials for the pharmaceutical and biopharmaceutical industries
Subscribe now